Gene activity in beta-thalassemia
Part of Blood & lymphatic clinical trials.
This study looks at the activity of a gene called EKLF in people with beta-thalassemia, a blood disorder that causes low hemoglobin and anemia. By measuring this gene, researchers hope to better understand the condition and find ways to improve treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with beta-thalassemia, either the major or intermedia form.
- People of any age and either sex can take part.
- You cannot have any other type of hemolytic anemia (a condition where red blood cells break down too quickly).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a one-time gene therapy using your own blood stem cells to treat severe beta-thalassemia. It may help you stop needing regular blood transfusions.
This trial tests a new gene therapy (BD211) for children and teens with severe beta-thalassemia who need regular blood transfusions. The treatment uses your own blood stem cells, modified with a working gene, to help your body make healthy red blood cells and reduce the need for transfusions.
This early-phase trial tests a new way to restore working blood-making cells using your own stem cells for people with transfusion-dependent beta thalassemia major. The goal is to improve safety and blood results, and possibly reduce problems from the disease.
This trial tests a one-time treatment that uses your own (autologous) stem cells that have been changed by gene methods, then returned to you to help manage transfusion-dependent beta-thalassemia. It aims to check safety and whether it can reduce the need for frequent blood transfusions or improve blood health.
This study looks for a specific genetic change (in the KLF1 gene) in people with beta thalassemia. If found, it might help explain how the disease runs in families.
This trial tests a new gene therapy for beta thalassemia. A modified virus is used to deliver a working gene to your blood stem cells, which may help your body produce normal hemoglobin and reduce the need for blood transfusions.
Hear when a new Thalassemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.